NOBODY does MHRA first. It is not a market that oncology marketers make much if any profit. U.S. is the gold mine and everybody who does trials under FDA jurisdiction, does it intending to file in the U.S. first. All other country regulators give FDA approved drugs faster reviews and most approve it based on the FDA's decision. But FDA told NWBO they didn't have sufficient clinical evidence to file. So NWBO had to find another country to file. UK is not a market anybody does first AFTER doing FDA sanctioned trials. That's the facts and the way it is playing out.
Market Data 
Markets 
